Showing posts with label Emami. Show all posts
Showing posts with label Emami. Show all posts
29 January 2015
16 November 2012
Emami -Q2FY13 – Sales in line, but EBITDA below:: Nomura
Are results above or below expectations?
Results were largely in-line with Street expectations and marginally
below our expectations at the EBITDA level.
Key numbers
Net sales grew 18% y-y and were largely in line with our and Street
expectations.
Domestic business grew 22%, which is fairly robust.
Exports (13% of revenues) were largely flat y-y and so was CSD (4%
of the revenues).
Brand-wise revenue growth details:
Cooling oil: +14% y-y
Boroplus: + 53% y-y
Balms: + 10% y-y
Fair & handsome: + 26% y-y
Gross margin expanded 50bps to 58.6%. This was largely in line with
what we were expecting.
However, A&P/sales: up 50bps y-y to 17.9%. This was a surprise;
however, we don't quite view this as a negative.
EBITDA: At INR896mn was 5% below our estimates and in-line with
Street expectations.
EBITDA margin: at 24.8% contracted 180bps y-y primarily due to
higher employee cost & advertising spends.
PAT: at INR612mn was up 7% y-y and in line with Street expectations,
but below ours on account of a higher tax rate.
CLICK links to Read MORE reports on:
Emami,
Nomura research
15 November 2012
Emami:: Outlook remains buoyant – Maintain BUY:: Religare
Outlook remains buoyant – Maintain BUY
HMN’s net sales/EBITDA/adj. PAT grew 17.9%/14.3%/7.6% YoY in Q2FY13, led by a strong 22% YoY growth in the domestic business and recovery in the international business. The onset of early winter has been good for the company with H2FY13 looking strong. We maintain BUY with a Sep’13 TP of Rs 635 on: (a) double-digit volume growth in the domestic business, (b) flattening out of input costs and (c) reasonable valuations at 25.9x/21.2x FY13E/FY14E P/E.
CLICK links to Read MORE reports on:
Emami,
religare research
18 June 2012
01 June 2012
14 May 2012
EMAMI LTD. CURRENT TREND : BULLISH Time Horizon : 6 Months Buy : Anand Rathi
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
--
Visit http://indiaer.blogspot.com/ for complete details �� ��
SCRIP NAME : EMAMI LTD. SECTOR : FMCG Date :14th May, 2012.
CURRENT TREND : BULLISH Time Horizon : 6 Months Buy in the Range of Rs.468-478 Stop loss Rs.434 (ON CLOSING BASIS )
TARGETS : 1st Target: Rs.554
2nd Target: Rs.580
SUPPORTING TECHNICAL COMMENTS
EMAMILTD - Rs. 475 , has been moving higher making higher lows on weekly basis and the stock looks very good to cross its all time high of Rs.545. The stock is trading above all major averages, with 20DMA Rs.456, 100DMA Rs.390 and 200DMA Rs.411. This FMCG stock is outperforming market with our other top picks like HINDUNILEVER, ITC and COLPAL .
Thanks & Regards
|
CLICK links to Read MORE reports on:
anand rathi,
Emami
04 April 2012
Emami - Amidst Price Hike & Acquisition ::Emkay PDF link
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Visit http://indiaer.blogspot.com/ for complete details �� ��
| ||
15 October 2011
UBS: Emami - Upgrade to Buy – niche product portfolio
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
UBS Investment Research
Emami Ltd
U pgrade to Buy – niche product portfolio
�� Event: Recent stock price easing, positive view compels us to revise rating
Emami stock price has eased c18% and underperformed BSE Sensex by c8% since
August 2011, possibly on high valuations earlier, increase in costs (menthol up
sharply; 16-17% of total cost) and a slightly lower expected volume growth of 8-
9% in Q2FY12 on weather. Emami is to take 6-7% price hikes in FY12 to offset
cost pressures. Our long-term outlook is positive and Emami is one of the fastest
growing consumer companies in India. H2 is seasonally stronger for Emami.
�� Impact: Maintain estimates and price target; upgrade to Buy
We maintain our FY12/13 estimates as we had earlier already incorporated a 14-
16% volume growth, 6-7% price hikes and lower margins. We also maintain price
target of Rs550. We estimate maximum impact of increase in menthol costs on
gross margins at 1-2%. Yet Emami is taking price hikes, optimising costs. We
think concerns are more than factored in stock price and we upgrade to Buy on
valuations (18.3x FY13E P/E; discount to peers) and positive long-term outlook.
�� Action: Continue to like their product portfolio, management capability
High brand loyalty for Emami’s products, 39-40% of sales through lower price
SKUs and health based products make it less likely to be impacted by potential
consumption cuts, innovative product launches, high ROEs and net cash position,
make us believe that Emami is an attractive Buy at current levels.
�� Valuation: Upgrade to Buy with a price target of Rs550
We derive our price target from a DCF-based methodology and explicitly forecast
long-term valuation drivers using UBS’s VCAM tool, at a WACC of 11.3%.
Visit http://indiaer.blogspot.com/ for complete details �� ��
UBS Investment Research
Emami Ltd
U pgrade to Buy – niche product portfolio
�� Event: Recent stock price easing, positive view compels us to revise rating
Emami stock price has eased c18% and underperformed BSE Sensex by c8% since
August 2011, possibly on high valuations earlier, increase in costs (menthol up
sharply; 16-17% of total cost) and a slightly lower expected volume growth of 8-
9% in Q2FY12 on weather. Emami is to take 6-7% price hikes in FY12 to offset
cost pressures. Our long-term outlook is positive and Emami is one of the fastest
growing consumer companies in India. H2 is seasonally stronger for Emami.
�� Impact: Maintain estimates and price target; upgrade to Buy
We maintain our FY12/13 estimates as we had earlier already incorporated a 14-
16% volume growth, 6-7% price hikes and lower margins. We also maintain price
target of Rs550. We estimate maximum impact of increase in menthol costs on
gross margins at 1-2%. Yet Emami is taking price hikes, optimising costs. We
think concerns are more than factored in stock price and we upgrade to Buy on
valuations (18.3x FY13E P/E; discount to peers) and positive long-term outlook.
�� Action: Continue to like their product portfolio, management capability
High brand loyalty for Emami’s products, 39-40% of sales through lower price
SKUs and health based products make it less likely to be impacted by potential
consumption cuts, innovative product launches, high ROEs and net cash position,
make us believe that Emami is an attractive Buy at current levels.
�� Valuation: Upgrade to Buy with a price target of Rs550
We derive our price target from a DCF-based methodology and explicitly forecast
long-term valuation drivers using UBS’s VCAM tool, at a WACC of 11.3%.
See full list -click link below:
UBS Mid-Caps Strategy - What to Buy? �� Oct 2011 Update
17 September 2011
UBS: Emami - London conference takeaways ; price target of Rs550
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
UBS Investment Research
Emami Ltd
L ondon conference takeaways
�� Event: key takeaways from the London Bat with India Inc conference
Management largely reiterated its positive outlook with its niche ayurvedic healthfocussed
product portfolio in under-penetrated categories, limited MNC
competition, and aggressive advertising spend. It is keen on evaluating M&A
opportunities (but no internal targets) and thinks Indian ayurvedic/cosmetic
companies are unlevered for any distressed buy-out opportunities. Mom-and-pop
shops are integral to distribution and there are no major hierarchy issues.
�� Impact: maintain our estimates and long-term positive view on the stock
We maintain our estimates and long-term positive outlook on the company based
on the company’s ability to innovate on new products and patiently incubate
categories. Sales growth in top five products and new launches is encouraging,
although we remain slightly cautious on raw material cost pressures.
�� Action: upside limited; niche health-based brands positive
Our Neutral rating reflects the limited upside potential on the stock on FY13
estimates. We are positive on Emami’s niche products, high gross margins and
plans to introduce a 6-7% price hike for FY12 to pass on high costs.
�� Valuation: Neutral rating with a price target of Rs550
We derive our price target from a DCF-based methodology and explicitly forecast
long-term valuation drivers using UBS’s VCAM tool. We assume a WACC of
11.3%.
Visit http://indiaer.blogspot.com/ for complete details �� ��
UBS Investment Research
Emami Ltd
L ondon conference takeaways
�� Event: key takeaways from the London Bat with India Inc conference
Management largely reiterated its positive outlook with its niche ayurvedic healthfocussed
product portfolio in under-penetrated categories, limited MNC
competition, and aggressive advertising spend. It is keen on evaluating M&A
opportunities (but no internal targets) and thinks Indian ayurvedic/cosmetic
companies are unlevered for any distressed buy-out opportunities. Mom-and-pop
shops are integral to distribution and there are no major hierarchy issues.
�� Impact: maintain our estimates and long-term positive view on the stock
We maintain our estimates and long-term positive outlook on the company based
on the company’s ability to innovate on new products and patiently incubate
categories. Sales growth in top five products and new launches is encouraging,
although we remain slightly cautious on raw material cost pressures.
�� Action: upside limited; niche health-based brands positive
Our Neutral rating reflects the limited upside potential on the stock on FY13
estimates. We are positive on Emami’s niche products, high gross margins and
plans to introduce a 6-7% price hike for FY12 to pass on high costs.
�� Valuation: Neutral rating with a price target of Rs550
We derive our price target from a DCF-based methodology and explicitly forecast
long-term valuation drivers using UBS’s VCAM tool. We assume a WACC of
11.3%.
15 September 2011
Emami::Takeaways Motilal Oswal Annual Global Investor Conferences
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Key Takeaways
Revenue growth target 20%+ over the next few years; Fair and Handsome,
Zandu to drive growth
Over the past five years, Emami (HMN) posted 25% revenue CAGR through strong
volume growth, judicious pricing and acquisitions (Zandu). The management is
confident of achieving 20%+ organic revenue growth over the next few years.
Fair and Handsome and Zandu posted 67% and 27% growth respectively in 1QFY12.
The management expects the brands to be main growth drivers in FY12 led by
strong activation and category growth.
Input cost pressures persist; Price hikes, cost savings to keep margins at
FY11 levels
Menthol prices (25% of RM) doubled over the past one year and rule firm and LLP
prices are up 40% YoY. HMN raised prices by 4% and plans another price increase
towards the end of 2QFY12.
Although gross margins are likely to be lower in FY12 with savings on A&P spends
(17-18% expected in FY12 v/s 19.5% in FY11) and operating leverage, the
management expects to maintain EBITDA margins at FY11 levels.
Bangladesh facility to become operational by 3QFY12, Egypt on hold, exports
do well
Exports increased 31% in 1QFY12 and the management is focused on increasing
distribution in focus markets of SAARC, Africa and the Middle East.
HMN's Bangladesh facility will become operational by 3QFY12. Egypt plans are on
hold and will be reviewed in a couple of quarters.
Emami open to domestic acquisitions, to consider opportunities when they
arise
Although international acquisition opportunities are many, HMN is keener on domestic
opportunities. There has been no activity regarding Paras Pharma's personal-care
brands and the management maintains it will evaluate the opportunity if it arises.
Valuation and view
HMN continues to grow ahead of its peers through niche positioning and leadership
in key categories. Margin pressure and acquisition intent in the domestic market will
be key factors to watch for in the near term.
The stock trades at 30.4x FY11 EPS of INR15.1. Not Rated.
Visit http://indiaer.blogspot.com/ for complete details �� ��
Key Takeaways
Revenue growth target 20%+ over the next few years; Fair and Handsome,
Zandu to drive growth
Over the past five years, Emami (HMN) posted 25% revenue CAGR through strong
volume growth, judicious pricing and acquisitions (Zandu). The management is
confident of achieving 20%+ organic revenue growth over the next few years.
Fair and Handsome and Zandu posted 67% and 27% growth respectively in 1QFY12.
The management expects the brands to be main growth drivers in FY12 led by
strong activation and category growth.
Input cost pressures persist; Price hikes, cost savings to keep margins at
FY11 levels
Menthol prices (25% of RM) doubled over the past one year and rule firm and LLP
prices are up 40% YoY. HMN raised prices by 4% and plans another price increase
towards the end of 2QFY12.
Although gross margins are likely to be lower in FY12 with savings on A&P spends
(17-18% expected in FY12 v/s 19.5% in FY11) and operating leverage, the
management expects to maintain EBITDA margins at FY11 levels.
Bangladesh facility to become operational by 3QFY12, Egypt on hold, exports
do well
Exports increased 31% in 1QFY12 and the management is focused on increasing
distribution in focus markets of SAARC, Africa and the Middle East.
HMN's Bangladesh facility will become operational by 3QFY12. Egypt plans are on
hold and will be reviewed in a couple of quarters.
Emami open to domestic acquisitions, to consider opportunities when they
arise
Although international acquisition opportunities are many, HMN is keener on domestic
opportunities. There has been no activity regarding Paras Pharma's personal-care
brands and the management maintains it will evaluate the opportunity if it arises.
Valuation and view
HMN continues to grow ahead of its peers through niche positioning and leadership
in key categories. Margin pressure and acquisition intent in the domestic market will
be key factors to watch for in the near term.
The stock trades at 30.4x FY11 EPS of INR15.1. Not Rated.
CLICK links to Read MORE reports on:
Emami,
Motilal oswal
14 September 2011
Emami (EMAM.BO, Buy, PT Rs550, 20% upside) UBS: India Mid-Caps TOP PICKS - September 2011
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
• One of India’s fastest-growing FMCG player (22.1% EPS CAGR
through FY11-13E)
• Niche ayurvedic/herbal product portfolio – health focus ensure
high brand loyalty; market leader in key brands (60% of sales)
• Presence in under-penetrated categories with limited MNC
competition supports higher gross margins (59-65%) than
peers
• Focused advertising, star power and brand development
supported by highest advertising spend (c18% of sales)
• Success in developing new categories and product variants – 2-
3 products/year
• Scale up of Zandu acquisition and over-the-counter (OTC)
products, international sales and new products to support
earnings growth
• Shareholding - Promoter 73%
• Valuation: DCF using UBS’s VCAM tool (assume WACC of
11.3% and terminal sales growth rate of 5%). Implied FY13PE
of 23.8x
CLICK HERE TO RETURN TO LIST OF UBS TOP PICK
Visit http://indiaer.blogspot.com/ for complete details �� ��
• One of India’s fastest-growing FMCG player (22.1% EPS CAGR
through FY11-13E)
• Niche ayurvedic/herbal product portfolio – health focus ensure
high brand loyalty; market leader in key brands (60% of sales)
• Presence in under-penetrated categories with limited MNC
competition supports higher gross margins (59-65%) than
peers
• Focused advertising, star power and brand development
supported by highest advertising spend (c18% of sales)
• Success in developing new categories and product variants – 2-
3 products/year
• Scale up of Zandu acquisition and over-the-counter (OTC)
products, international sales and new products to support
earnings growth
• Shareholding - Promoter 73%
• Valuation: DCF using UBS’s VCAM tool (assume WACC of
11.3% and terminal sales growth rate of 5%). Implied FY13PE
of 23.8x
CLICK HERE TO RETURN TO LIST OF UBS TOP PICK
19 August 2011
UBS :: Emami Ltd - Niche, health based products positive ; Downgrade to Neutral
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
UBS Investment Research
Emami Ltd
N iche, health based products positive
Event: Q1FY12 results in line; strong revenue growth but higher costs
Emami reported Q1FY12 PAT of Rs415mn, up 17.7% YoY, in line with our and
consensus estimates, supported by a robust 24% revenue growth (16% volume, rest
pricing) and lower tax rate of 3.1% (deferred tax benefit). Raw material costs
continue to remain high at 44.9% of sales and Emami has taken judicious price
hikes in the quarter and expects a 6-7% increase in FY12.
Impact: Maintain estimates, but upgrade PT on roll over to FY13E
We broadly maintain our FY12/13 estimates as we have increased revenue growth
from earlier 17-18% for FY12/13E to 22-23% (6-7% price hike in FY12) but with
a lower margin assumption (gross at 58.5/59% in FY12/13) on high raw material
prices and a tax rate of 12% for FY12E. We upgrade the price target to Rs550 as
we roll over to FY13E but downgrade the stock to Neutral.
Action: Upsides now limited; niche health based brands positive
Despite our price target upgrade (implied 9.7% discount of Dabur), the potential
upside looks limited due to the recent out-performance (23.5% in last 3 months
compared to Nifty) due to robust revenue growth and the defensive nature of the
stock. It is at a P/E of 26.4x FY12E and 21.0x FY13E estimates. Our Neutral rating
reflects the limited upside potential to the stock on FY13E estimates. We are quite
positive on Emami’s niche products, high gross margins and its significant
innovation ability.
Valuation: Downgrade to Neutral with a price target of Rs550
We derive our price target from a DCF-based methodology and explicitly forecast
long-term valuation drivers using UBS’s VCAM tool, at a WACC of 11.3%.
Visit http://indiaer.blogspot.com/ for complete details �� ��
UBS Investment Research
Emami Ltd
N iche, health based products positive
Event: Q1FY12 results in line; strong revenue growth but higher costs
Emami reported Q1FY12 PAT of Rs415mn, up 17.7% YoY, in line with our and
consensus estimates, supported by a robust 24% revenue growth (16% volume, rest
pricing) and lower tax rate of 3.1% (deferred tax benefit). Raw material costs
continue to remain high at 44.9% of sales and Emami has taken judicious price
hikes in the quarter and expects a 6-7% increase in FY12.
Impact: Maintain estimates, but upgrade PT on roll over to FY13E
We broadly maintain our FY12/13 estimates as we have increased revenue growth
from earlier 17-18% for FY12/13E to 22-23% (6-7% price hike in FY12) but with
a lower margin assumption (gross at 58.5/59% in FY12/13) on high raw material
prices and a tax rate of 12% for FY12E. We upgrade the price target to Rs550 as
we roll over to FY13E but downgrade the stock to Neutral.
Action: Upsides now limited; niche health based brands positive
Despite our price target upgrade (implied 9.7% discount of Dabur), the potential
upside looks limited due to the recent out-performance (23.5% in last 3 months
compared to Nifty) due to robust revenue growth and the defensive nature of the
stock. It is at a P/E of 26.4x FY12E and 21.0x FY13E estimates. Our Neutral rating
reflects the limited upside potential to the stock on FY13E estimates. We are quite
positive on Emami’s niche products, high gross margins and its significant
innovation ability.
Valuation: Downgrade to Neutral with a price target of Rs550
We derive our price target from a DCF-based methodology and explicitly forecast
long-term valuation drivers using UBS’s VCAM tool, at a WACC of 11.3%.
11 June 2011
Emami: Buy; PT Rs535 :: UBS India Mid-Cap Premier League - Season 1
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami: Buy; PT Rs535
Management expects to retain market leadership and maintain 14-18% sales
growth in top 4-5 brands. Expect Rs400-600mn spending every year in
developing new brands with 2-3 product launches each year.
Strong focus on personal care category and also aim to revive Zandu’s OTC
products.
Newer products like Navratna Extra Thanda Oil, Navratna Cooling Talc has
recorded high sales growth. Accordingly it believes that given the
competition and lower product-life cycle, brand extension remains the key to
lower the break-even period of product.
Management indicated raw material costs are likely to be maintained and
company is evaluating price hikes and grammage reductions. Advertising
expenses are likely to remain at 18%, and slight tapering could be likely.
M&A potential will likely depend on synergistic opportunities and
management has earlier indicated that they could value deals at a premium if
it makes strong business sense over the long term. Their break-even
benchmark is 5-7 years.
Strategy of deeper penetration, strong distribution, focused advertisements
should drive category growth. Today’s lifestyle and ayurvedic products
(given its good acceptance) should drive the growth. Ayurveda is not wellmarketed
in India.
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami: Buy; PT Rs535
Management expects to retain market leadership and maintain 14-18% sales
growth in top 4-5 brands. Expect Rs400-600mn spending every year in
developing new brands with 2-3 product launches each year.
Strong focus on personal care category and also aim to revive Zandu’s OTC
products.
Newer products like Navratna Extra Thanda Oil, Navratna Cooling Talc has
recorded high sales growth. Accordingly it believes that given the
competition and lower product-life cycle, brand extension remains the key to
lower the break-even period of product.
Management indicated raw material costs are likely to be maintained and
company is evaluating price hikes and grammage reductions. Advertising
expenses are likely to remain at 18%, and slight tapering could be likely.
M&A potential will likely depend on synergistic opportunities and
management has earlier indicated that they could value deals at a premium if
it makes strong business sense over the long term. Their break-even
benchmark is 5-7 years.
Strategy of deeper penetration, strong distribution, focused advertisements
should drive category growth. Today’s lifestyle and ayurvedic products
(given its good acceptance) should drive the growth. Ayurveda is not wellmarketed
in India.
08 June 2011
UBS:: Emami Ltd - On a favourable growth trajectory -Buy Rs535.00 price target
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
UBS Investment Research
Emami Ltd
O n a favourable growth trajectory [EXTRACT]
Niche, ayurvedic-based products with significant loyalty and mass appeal
Emami is one of India’s fastest-growing fast moving consumer goods (FMCG)
companies with a niche product portfolio focused on ayurvedic and herbal
formulations (health focus leads to strong brand loyalty), which have mass appeal
in India. Emami's brands of ‘cooling’ oil and antiseptic creams are generically
identified with the category itself. These supported its strong gross margins of 59-
65% in FY08-11, aiding a high advertising spend (18% of total sales in FY11) for
national/regional marketing.
Market leader in under-penetrated segments; growth from new products
Emami is a market leader in four key products (60% of its sales)—Navratna
Cooling Oil, Boroplus Cream, Zandu Balm, and Fair Handsome Cream. It has
presence in under-penetrated categories with limited multinational corporation
(MNC) competition. Newer products such as Navratna Extra Thanda Oil, ‘cooling
talc’, Vasocare and cold creams should support sales growth (16.4% of sales in
FY11). We think additional growth drivers are its expanding distribution and rural
reach, a scaling up in its Zandu business operations, and strong international sales.
Forecast 22.1% EPS CAGR in FY11-13; net cash balance sheet in FY12E
We forecast a 22.1% net income CAGR over FY11-13, assuming a 17.7% sales
CAGR and slight improvements in its gross margin (19.8-21.1% in FY11-13E)
from a partial cost pass-through and tapering advertising expenses. Net nonoperating
income and low tax rates should also support earnings growth.
Valuation: initiate coverage with a Buy rating and Rs535.00 price target
We derive our price target from a DCF-based methodology and explicitly forecast
long-term valuation drivers using UBS’s VCAM tool, assuming a WACC of 11%.
Our price target implies 23.7x FY13E PE.
Visit http://indiaer.blogspot.com/ for complete details �� ��
UBS Investment Research
Emami Ltd
O n a favourable growth trajectory [EXTRACT]
Niche, ayurvedic-based products with significant loyalty and mass appeal
Emami is one of India’s fastest-growing fast moving consumer goods (FMCG)
companies with a niche product portfolio focused on ayurvedic and herbal
formulations (health focus leads to strong brand loyalty), which have mass appeal
in India. Emami's brands of ‘cooling’ oil and antiseptic creams are generically
identified with the category itself. These supported its strong gross margins of 59-
65% in FY08-11, aiding a high advertising spend (18% of total sales in FY11) for
national/regional marketing.
Market leader in under-penetrated segments; growth from new products
Emami is a market leader in four key products (60% of its sales)—Navratna
Cooling Oil, Boroplus Cream, Zandu Balm, and Fair Handsome Cream. It has
presence in under-penetrated categories with limited multinational corporation
(MNC) competition. Newer products such as Navratna Extra Thanda Oil, ‘cooling
talc’, Vasocare and cold creams should support sales growth (16.4% of sales in
FY11). We think additional growth drivers are its expanding distribution and rural
reach, a scaling up in its Zandu business operations, and strong international sales.
Forecast 22.1% EPS CAGR in FY11-13; net cash balance sheet in FY12E
We forecast a 22.1% net income CAGR over FY11-13, assuming a 17.7% sales
CAGR and slight improvements in its gross margin (19.8-21.1% in FY11-13E)
from a partial cost pass-through and tapering advertising expenses. Net nonoperating
income and low tax rates should also support earnings growth.
Valuation: initiate coverage with a Buy rating and Rs535.00 price target
We derive our price target from a DCF-based methodology and explicitly forecast
long-term valuation drivers using UBS’s VCAM tool, assuming a WACC of 11%.
Our price target implies 23.7x FY13E PE.
24 May 2011
Emami --In-line 4Q; early signs of costs ease .:Macquarie Research
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami
In-line 4Q; early signs of costs ease
Event
Emami reported in-line 4Q’FY11 results; sales grew by 26%YoY and PAT grew
by 17%YoY. While net profit was almost in-line with our expectation, sales were
4% ahead of our estimates. The company reported 19% domestic volume
growth with strong growth across all key products. Export growth was a robust
34% YoY, backed by South Asia and Africa. We reiterate our Outperform.
Impact
Robust 26% sales growth, assisted by 19% volume growth. Emami’s 4Q
FY11 sales grew by 26%YoY to Rs3.5bn, led by 19% domestic volume and
the impact of a ~4% weighted price hike in India. Sales growth was supported
by strong growth in key brands: Navratna Hair Oil (↑19%), Zandu Balm (↑
20%) and Navratna Cool Talc (↑ 90%), Mentho Plus Balm (↑ 21%),
International sales (↑34%) and Boroplus Prickly Heat Powder (↑ 11%).
Early signs of ease in raw material (RM) prices. Emami’s EBITDA margin
declined 489bp due to a 273bp drop in gross margin on higher RM costs, and
an increase in employee costs due to the addition of a 300 sales force to grow
international sales and increase rural penetration. Prices of key raw materials
like menthol (↑75% YoY) and LLP (↑25% YoY) has impacted gross margins.
Early signs of a cool-off in raw material costs are visible as menthol prices
have come down ~13% since their April peak ahead of fresh crop in June. We
see low probability of downside risks to margins from 2Q’FY12E.
Net profit grew by 17% YoY to Rs550mn. PAT growth was aided by strong
26% top-line growth, interest income (compared to expense in the previous year)
and higher other income. We believe stabilisation in raw material prices along with
a fast growing product portfolio with a low near-term competitive threat will help
the company post a ~20% earnings CAGR over the next three years.
New product initiatives continue. Emami has been aggressive in new product
launches with significant successes over the last 4-5 years. Emami is planning
to enter underpenetrated skincare categories with technology from Mibelle
Biochemistry and it intends to roll out these products from 2H’FY12. The
company also plans to roll out coconut-based Ayurvedic hair oil nationally.
Earnings and target price revision
We have cut our FY12E EPS by ~4% and maintain our TP to Rs550.
Price catalyst
12-month price target: Rs550.00 based on a DCF methodology.
Catalyst: Decline in raw material prices
Action and recommendation
Outperform maintained. We maintain our positive view on Emami, given its
strong growth momentum, healthy product pipeline and new initiatives, which
should add growth and maintain leadership in key products. We expect
Emami to record a 20% earnings CAGR over the next three years.
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami
In-line 4Q; early signs of costs ease
Event
Emami reported in-line 4Q’FY11 results; sales grew by 26%YoY and PAT grew
by 17%YoY. While net profit was almost in-line with our expectation, sales were
4% ahead of our estimates. The company reported 19% domestic volume
growth with strong growth across all key products. Export growth was a robust
34% YoY, backed by South Asia and Africa. We reiterate our Outperform.
Impact
Robust 26% sales growth, assisted by 19% volume growth. Emami’s 4Q
FY11 sales grew by 26%YoY to Rs3.5bn, led by 19% domestic volume and
the impact of a ~4% weighted price hike in India. Sales growth was supported
by strong growth in key brands: Navratna Hair Oil (↑19%), Zandu Balm (↑
20%) and Navratna Cool Talc (↑ 90%), Mentho Plus Balm (↑ 21%),
International sales (↑34%) and Boroplus Prickly Heat Powder (↑ 11%).
Early signs of ease in raw material (RM) prices. Emami’s EBITDA margin
declined 489bp due to a 273bp drop in gross margin on higher RM costs, and
an increase in employee costs due to the addition of a 300 sales force to grow
international sales and increase rural penetration. Prices of key raw materials
like menthol (↑75% YoY) and LLP (↑25% YoY) has impacted gross margins.
Early signs of a cool-off in raw material costs are visible as menthol prices
have come down ~13% since their April peak ahead of fresh crop in June. We
see low probability of downside risks to margins from 2Q’FY12E.
Net profit grew by 17% YoY to Rs550mn. PAT growth was aided by strong
26% top-line growth, interest income (compared to expense in the previous year)
and higher other income. We believe stabilisation in raw material prices along with
a fast growing product portfolio with a low near-term competitive threat will help
the company post a ~20% earnings CAGR over the next three years.
New product initiatives continue. Emami has been aggressive in new product
launches with significant successes over the last 4-5 years. Emami is planning
to enter underpenetrated skincare categories with technology from Mibelle
Biochemistry and it intends to roll out these products from 2H’FY12. The
company also plans to roll out coconut-based Ayurvedic hair oil nationally.
Earnings and target price revision
We have cut our FY12E EPS by ~4% and maintain our TP to Rs550.
Price catalyst
12-month price target: Rs550.00 based on a DCF methodology.
Catalyst: Decline in raw material prices
Action and recommendation
Outperform maintained. We maintain our positive view on Emami, given its
strong growth momentum, healthy product pipeline and new initiatives, which
should add growth and maintain leadership in key products. We expect
Emami to record a 20% earnings CAGR over the next three years.
CLICK links to Read MORE reports on:
Emami,
Macquarie Research
09 April 2011
Excerpts from IIFL’s interview with the founders of Emami, RS Agarwal and RS Goenka
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Excerpts from IIFL’s interview
with the founders of Emami, RS Agarwal and RS
Goenka
We met the co-founders of Emami in Kolkata. They discussed
the beginnings of Emami and how the company has used
product differentiation as the central pillar of their strategy.
They also outlined their approach towards organisation
building and implementing systems and processes as the
company looks to transform to a much larger scale.
Tell us about the beginnings of Emami.
RS Agarwal: We used to study in the same school and became very
close friends. After graduation, we used to meet almost every day
and started thinking about what we could do together, and decided
to start a small business together. That is how the journey started.
With an initial investment of Rs20,000, we started our business from
a 60-sq-ft space in the godown. Our first big success came in 1974,
we launched the Emami brand name and launched talcum powders
and vanishing creams under the brand name. Both products were
hugely successful—so much so that in talcum powder, we became
the second-largest player in the country and in vanishing cream, we
actually became the market leader, beating established MNC brands.
How did you go about the key marketing tasks—branding,
product design, etc?
RS Agarwal: Right from the start, our mantra has been
distinctiveness, differentiation and innovation. We studied the gaps
in portfolios of the top FMCG companies, and we tried to use these
gaps to position our brands. When all other established brands were
selling skin creams in tin containers, Emami was the first to come up
with plastic packaging, which was a refreshing change and looked
significantly better. While all established brands were using cheaper
perfume, we came with French perfume in our talcum powder and
creams. If you ask consumers who bought these products around
the 1970s, they still remember the perfume of Emami talcum
powder—it was so distinctive. We have followed the same mantra of
distinctiveness, differentiation and innovation in creating Boro Plus,
Navratna Oil and Fair & Handsome. Ours is the first company to have
come up with advertising in Hindi movies, a medium that was
probably the only form of entertainment for most people in the
1970s. So there was distinctiveness even in our style of advertising.
Were there failures in new products?
RS Goenka: Whenever the company faced any difficulty in any new
product launch, we were very fast to take decisions and withdraw
before any major loss was incurred. Our feedback mechanism and
MIS has been very strong from the very beginning, and this has
been the biggest reason we have managed to avoid major failures.
What has been your approach towards systems & processes?
RS Goenka: Our experience of having worked in the corporate world
stood us in good stead. For instance, from the very beginning, we
put in place a strong MIS for all parts of our business, be it sales,
purchase, manufacturing or supply chain. As early as 2003, we
introduced ERP in our company, when even many of the large MNC
FMCG companies in India were operating on far inferior IT systems.
We have a large internal audit team with over 60 persons who
constantly audit operations, including forensic audit. Beyond this,
whenever we need to look at improvements in our operations, we
appoint best-in-class consultants to give us the advice.
Emami group has very large businesses outside of FMCG.
RS Goenka: We are today one of the largest business groups in
eastern India. We are the India’s largest player in newsprint. In
hospitals, we are the biggest private sector player in the eastern
zone. We have a pharmacy chain, which is the biggest in the eastern
zone, and probably the biggest in the country after Apollo. In real
estate, what we have built in Bengal would be a matter of pride for
anyone.
There is a perception that Emami is a family-run business and
hence professionals do not work in the senior.
RS Agarwal: There is a big difference between owners running a
company and professional owners managing a company. We are
professional owners. Both Goenkaji and I have strong higher
education backgrounds and we have worked in the corporate world
in important positions. If I am a chartered accountant, MCom, LLB,
FCS, am I not a professional myself? Today, we have around 140
MBAs and around 100 CAs working in our group.
Emami has a diverse set of business and a number of family
members are involved in running the businesses. What are
the key aspects of managing such a structure?
RS Agarwal: To begin with, each of the companies in our group is a
completely separate entity. None of our companies can fund another
within the group. In each company, one member of the second
generation from each of the two families is involved. Either Goenkaji
or I is chairman of each company. We have very well-defined and
documented rules for all family members. The rules cover a large
number of aspects—owning fixed assets, making investments,
personal expenses, and so on. Independent directors on our board
include the former chairman of Ernst & Young India, Mr K N Memani;
former governor of West Bengal Mr Viren J Shah; and eminent
lawyer Mr Y P Trivedi.
How do you evaluate acquisitions?
RS Goenka: Way back in 1982, we took over Himani, which was a
sick business in Kolkata. We launched Boro Plus cream in 1983 and
followed it up with Navratna oil under the Himani brand name. We
acquired Zandu for a price that many analysts then thought was too
high, but it was based on a very thorough and highly detailed
internal analysis of potential returns. We were clear that Zandu was
a valuable franchise, and would generate very high returns after cost
rationalisation. Sure enough, profits multiplied 4x within 1-2 years
after we took over the company. The Zandu brand’s revenues, which
were growing at less than 10% annually, are today growing higher
than 30%, thanks to our innovative marketing strategy. The same
rigorous process of evaluation was done for Paras Pharmaceuticals
when we bid for the company. The evaluation was done for every
product in the Paras portfolio, looking at possible synergies and
opportunities for growth. We know the value of money as we started
very small and are very careful when we use our resources.
Visit http://indiaer.blogspot.com/ for complete details �� ��
Excerpts from IIFL’s interview
with the founders of Emami, RS Agarwal and RS
Goenka
We met the co-founders of Emami in Kolkata. They discussed
the beginnings of Emami and how the company has used
product differentiation as the central pillar of their strategy.
They also outlined their approach towards organisation
building and implementing systems and processes as the
company looks to transform to a much larger scale.
Tell us about the beginnings of Emami.
RS Agarwal: We used to study in the same school and became very
close friends. After graduation, we used to meet almost every day
and started thinking about what we could do together, and decided
to start a small business together. That is how the journey started.
With an initial investment of Rs20,000, we started our business from
a 60-sq-ft space in the godown. Our first big success came in 1974,
we launched the Emami brand name and launched talcum powders
and vanishing creams under the brand name. Both products were
hugely successful—so much so that in talcum powder, we became
the second-largest player in the country and in vanishing cream, we
actually became the market leader, beating established MNC brands.
How did you go about the key marketing tasks—branding,
product design, etc?
RS Agarwal: Right from the start, our mantra has been
distinctiveness, differentiation and innovation. We studied the gaps
in portfolios of the top FMCG companies, and we tried to use these
gaps to position our brands. When all other established brands were
selling skin creams in tin containers, Emami was the first to come up
with plastic packaging, which was a refreshing change and looked
significantly better. While all established brands were using cheaper
perfume, we came with French perfume in our talcum powder and
creams. If you ask consumers who bought these products around
the 1970s, they still remember the perfume of Emami talcum
powder—it was so distinctive. We have followed the same mantra of
distinctiveness, differentiation and innovation in creating Boro Plus,
Navratna Oil and Fair & Handsome. Ours is the first company to have
come up with advertising in Hindi movies, a medium that was
probably the only form of entertainment for most people in the
1970s. So there was distinctiveness even in our style of advertising.
Were there failures in new products?
RS Goenka: Whenever the company faced any difficulty in any new
product launch, we were very fast to take decisions and withdraw
before any major loss was incurred. Our feedback mechanism and
MIS has been very strong from the very beginning, and this has
been the biggest reason we have managed to avoid major failures.
What has been your approach towards systems & processes?
RS Goenka: Our experience of having worked in the corporate world
stood us in good stead. For instance, from the very beginning, we
put in place a strong MIS for all parts of our business, be it sales,
purchase, manufacturing or supply chain. As early as 2003, we
introduced ERP in our company, when even many of the large MNC
FMCG companies in India were operating on far inferior IT systems.
We have a large internal audit team with over 60 persons who
constantly audit operations, including forensic audit. Beyond this,
whenever we need to look at improvements in our operations, we
appoint best-in-class consultants to give us the advice.
Emami group has very large businesses outside of FMCG.
RS Goenka: We are today one of the largest business groups in
eastern India. We are the India’s largest player in newsprint. In
hospitals, we are the biggest private sector player in the eastern
zone. We have a pharmacy chain, which is the biggest in the eastern
zone, and probably the biggest in the country after Apollo. In real
estate, what we have built in Bengal would be a matter of pride for
anyone.
There is a perception that Emami is a family-run business and
hence professionals do not work in the senior.
RS Agarwal: There is a big difference between owners running a
company and professional owners managing a company. We are
professional owners. Both Goenkaji and I have strong higher
education backgrounds and we have worked in the corporate world
in important positions. If I am a chartered accountant, MCom, LLB,
FCS, am I not a professional myself? Today, we have around 140
MBAs and around 100 CAs working in our group.
Emami has a diverse set of business and a number of family
members are involved in running the businesses. What are
the key aspects of managing such a structure?
RS Agarwal: To begin with, each of the companies in our group is a
completely separate entity. None of our companies can fund another
within the group. In each company, one member of the second
generation from each of the two families is involved. Either Goenkaji
or I is chairman of each company. We have very well-defined and
documented rules for all family members. The rules cover a large
number of aspects—owning fixed assets, making investments,
personal expenses, and so on. Independent directors on our board
include the former chairman of Ernst & Young India, Mr K N Memani;
former governor of West Bengal Mr Viren J Shah; and eminent
lawyer Mr Y P Trivedi.
How do you evaluate acquisitions?
RS Goenka: Way back in 1982, we took over Himani, which was a
sick business in Kolkata. We launched Boro Plus cream in 1983 and
followed it up with Navratna oil under the Himani brand name. We
acquired Zandu for a price that many analysts then thought was too
high, but it was based on a very thorough and highly detailed
internal analysis of potential returns. We were clear that Zandu was
a valuable franchise, and would generate very high returns after cost
rationalisation. Sure enough, profits multiplied 4x within 1-2 years
after we took over the company. The Zandu brand’s revenues, which
were growing at less than 10% annually, are today growing higher
than 30%, thanks to our innovative marketing strategy. The same
rigorous process of evaluation was done for Paras Pharmaceuticals
when we bid for the company. The evaluation was done for every
product in the Paras portfolio, looking at possible synergies and
opportunities for growth. We know the value of money as we started
very small and are very careful when we use our resources.
Emami BUY - The niche advantage :traget Rs 490: IIFL
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami BUY - The niche advantage
Emami is one of India’s fastest-growing FMCG companies,
with a unique product mix of leadership positions in niche
segments such as ‘cooling oils’, pain balms and antiseptic
creams. With minimal competition from large companies,
Emami commands high pricing power, which would help it
tide over commodity inflation. Growth in low-penetration core
categories, product innovation and expansion in the
international business will drive 24% earnings CAGR over
FY10-13. Margin pressures and an expensive bid for Paras
Pharmaceuticals have led to a correction of 24% in the past
six months, which we believe is an attractive entry point into
the stock.
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami BUY - The niche advantage
Emami is one of India’s fastest-growing FMCG companies,
with a unique product mix of leadership positions in niche
segments such as ‘cooling oils’, pain balms and antiseptic
creams. With minimal competition from large companies,
Emami commands high pricing power, which would help it
tide over commodity inflation. Growth in low-penetration core
categories, product innovation and expansion in the
international business will drive 24% earnings CAGR over
FY10-13. Margin pressures and an expensive bid for Paras
Pharmaceuticals have led to a correction of 24% in the past
six months, which we believe is an attractive entry point into
the stock.
17 February 2011
Macquarie Research, :: Emami -Creating a niche in personal care
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami
Creating a niche in personal care
Event
Emami is a key player in the niche „therapeutic‟ and „ayurvedic‟ segments of
the personal care and consumer healthcare categories. With over 30 brands
under its portfolio, Emami has grown at a 25% CAGR over the last few years.
Emami has four brands with sales greater than Rs1bn, and the company
plans to expand its “billion rupee brands” to six over the next two years.
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami
Creating a niche in personal care
Event
Emami is a key player in the niche „therapeutic‟ and „ayurvedic‟ segments of
the personal care and consumer healthcare categories. With over 30 brands
under its portfolio, Emami has grown at a 25% CAGR over the last few years.
Emami has four brands with sales greater than Rs1bn, and the company
plans to expand its “billion rupee brands” to six over the next two years.
CLICK links to Read MORE reports on:
Emami,
Macquarie Research
02 February 2011
Emami 3QFY11 – Revenue growth buoyant; retain Buy: Anand Rathi
Please Share::
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami
3QFY11 – Revenue growth buoyant; retain Buy
Emami reported 3QFY11 revenue and PAT growth of 16% and
9% respectively. The company maintained healthy volume
growth despite inflationary pressures. Though 3QFY11 margin is
lower, we remain positive on Emami’s growth prospects and
expect earnings CAGR of 27% over FY10-13e; reiterate Buy
Visit http://indiaer.blogspot.com/ for complete details �� ��
Emami
3QFY11 – Revenue growth buoyant; retain Buy
Emami reported 3QFY11 revenue and PAT growth of 16% and
9% respectively. The company maintained healthy volume
growth despite inflationary pressures. Though 3QFY11 margin is
lower, we remain positive on Emami’s growth prospects and
expect earnings CAGR of 27% over FY10-13e; reiterate Buy
CLICK links to Read MORE reports on:
anand rathi,
Emami
Subscribe to:
Posts (Atom)